ASP Isotopes Inc. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: ASP Isotopes Inc. (ASPI)
Reporting Period: Year ended December 31, 2024
Business Model: ASP Isotopes is a development-stage advanced materials company focused on isotope enrichment technologies: the Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE). The company operates two segments: Specialist Isotopes and Related Services (medical, semiconductor, and agrochemical isotopes) and Nuclear Fuels (HALEU and Lithium-6).
Key Milestones: The company completed commissioning of C-14 and Si-28 facilities in South Africa and is commencing commercial production. It also acquired a 51% stake in PET Labs Pharmaceuticals to enter the downstream radiopharmacy market.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $4.14 million | $0.43 million |
| Gross Profit | $1.60 million | $0.14 million |
| Net Loss | $(32.42) million | $(16.29) million |
| Operating Expenses | $27.95 million | $16.18 million |
| Cash and Cash Equivalents | $61.89 million | $7.91 million |
| Convertible Notes Payable (Fair Value) | $33.43 million | $0 |
| Accumulated Deficit | $(56.17) million | $(23.84) million |
Note: The Net Loss includes a non-cash charge of $6.88 million related to the change in fair value of convertible notes payable.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 857% to $4.14 million, driven primarily by the acquisition of PET Labs (product revenue of $3.94 million) and collaboration revenue of $0.20 million from TerraPower.
- Expense Increase: Operating expenses rose by 73% to $27.95 million. Selling, General, and Administrative (SG&A) expenses increased by $9.40 million, largely due to higher personnel costs, legal fees related to shareholder litigation, and financing commissions. R&D expenses increased by $2.37 million due to expanded headcount and facility costs.
- Liquidity Position: Cash balances surged from $7.91 million to $61.89 million, fueled by $82.53 million in net financing activities, including public equity offerings and convertible note issuances.
- Segment Reporting: The company transitioned from a single operating segment to two segments (Nuclear Fuels and Specialist Isotopes) in 2024.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Commercial Production: The company expects to ship first commercial batches of C-14 in mid-2025 and Si-28 in Q2 2025. Yb-176 production is expected to commence in Q2 2025.
- HALEU Initiative: A term sheet with TerraPower contemplates funding for a HALEU facility in South Africa, with a target completion in 2027. An MOU with South Africa's Necsa supports this initiative.
- Spin-out Plan: Management plans to spin out the Quantum Leap Energy (QLE) subsidiary as a separate public company.
Risks and Contingencies:
- Profitability: The company has incurred losses since inception and expects to continue incurring significant losses. It has no revenue from enriched isotopes to date.
- Capital Needs: While current cash is sufficient for 12+ months, substantial additional capital will be required for commercialization and facility construction.
- Legal Proceedings: A putative securities class action was filed in December 2024 alleging misleading statements regarding the business.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting related to lack of formal documentation, insufficient personnel, and IT security issues.
- Regulatory: Operations are subject to strict nuclear regulations (IAEA, NPT) and export controls. Regulatory approval for medical isotopes and uranium enrichment is uncertain.
Investor Verification Checklist
- Commercialization Timeline: Verify the actual shipment dates for C-14, Si-28, and Yb-176 against the projected mid-2025/Q2 2025 targets.
- Internal Control Remediation: Monitor progress on remediation of the material weakness in internal controls to ensure future financial reporting reliability.
- Convertible Note Valuation: Assess the impact of the $33.4 million fair value liability on future earnings, as fluctuations in stock price will drive non-cash gains/losses.
- Legal Litigation: Track the status of the Corredor v. ASP Isotopes Inc. securities class action filed in December 2024.
- HALEU Funding: Confirm the execution of definitive agreements with TerraPower and the receipt of funding for the HALEU facility construction.
- QLE Spin-out: Evaluate the feasibility and timeline for the planned spin-out of the Quantum Leap Energy subsidiary.